EVX1
geneOn this page
Summary
EVX1 (even-skipped homeobox 1, HGNC:3506) is a protein-coding gene on chromosome 7p15.2, encoding Homeobox even-skipped homolog protein 1 (P49640). May play a role in the specification of neuronal cell types.
This gene encodes a member of the even-skipped homeobox family characterized by the presence of a homeodomain closely related to the Drosophila even-skipped (eve) segmentation gene of the pair-rule class. The encoded protein may play an important role as a transcriptional repressor during embryogenesis.
Source: NCBI Gene 2128 — RefSeq curated summary.
At a glance
- GWAS associations: 31
- Clinical variants (ClinVar): 76 total — 1 pathogenic
- MANE Select transcript:
NM_001989
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:3506 |
| Approved symbol | EVX1 |
| Name | even-skipped homeobox 1 |
| Location | 7p15.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000106038 |
| Ensembl biotype | protein_coding |
| OMIM | 142996 |
| Entrez | 2128 |
Gene structure
Transcript identifiers
Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined
ENST00000222761, ENST00000496902, ENST00000518886, ENST00000580535
RefSeq mRNA: 3 — MANE Select: NM_001989
NM_001304519, NM_001304520, NM_001989
CCDS: CCDS5413
Canonical transcript exons
ENST00000496902 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000832103 | 27242802 | 27243457 |
| ENSE00001891220 | 27245886 | 27247830 |
| ENSE00003630409 | 27245048 | 27245304 |
Expression profiles
Bgee: expression breadth ubiquitous, 144 present calls, max score 95.68.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0872 / max 11.6626, expressed in 39 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 77819 | 0.0585 | 27 |
| 77818 | 0.0286 | 13 |
Top tissues by expression
222 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| type B pancreatic cell | CL:0000169 | 95.68 | silver quality |
| olfactory bulb | UBERON:0002264 | 95.66 | silver quality |
| cervix squamous epithelium | UBERON:0006922 | 93.34 | silver quality |
| vena cava | UBERON:0004087 | 92.71 | gold quality |
| cardia of stomach | UBERON:0001162 | 92.20 | silver quality |
| body of tongue | UBERON:0011876 | 91.64 | gold quality |
| renal medulla | UBERON:0000362 | 91.30 | gold quality |
| male germ cell | CL:0000015 | 91.22 | silver quality |
| sperm | CL:0000019 | 90.71 | silver quality |
| tongue | UBERON:0001723 | 90.67 | silver quality |
| subthalamic nucleus | UBERON:0001906 | 90.56 | silver quality |
| ventral tegmental area | UBERON:0002691 | 90.55 | silver quality |
| inferior vagus X ganglion | UBERON:0005363 | 90.49 | silver quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 90.43 | gold quality |
| dorsal plus ventral thalamus | UBERON:0001897 | 90.14 | silver quality |
| pylorus | UBERON:0001166 | 90.11 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 90.05 | silver quality |
| nipple | UBERON:0002030 | 89.80 | silver quality |
| pericardium | UBERON:0002407 | 89.75 | gold quality |
| lateral nuclear group of thalamus | UBERON:0002736 | 89.56 | silver quality |
| superior surface of tongue | UBERON:0007371 | 89.52 | silver quality |
| lateral globus pallidus | UBERON:0002476 | 89.35 | silver quality |
| triceps brachii | UBERON:0001509 | 89.25 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 89.22 | silver quality |
| trachea | UBERON:0003126 | 89.13 | silver quality |
| cervix epithelium | UBERON:0004801 | 88.99 | silver quality |
| substantia nigra pars compacta | UBERON:0001965 | 88.79 | silver quality |
| pons | UBERON:0000988 | 88.77 | silver quality |
| pharyngeal mucosa | UBERON:0000355 | 88.76 | silver quality |
| trigeminal ganglion | UBERON:0001675 | 88.64 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 1.95 |
Regulation
Is transcription factor: yes
Downstream targets (CollecTRI)
4 targets.
| Target | Regulation |
|---|---|
| GSC | Repression |
| INHBA | |
| SLU7 | |
| TNC | Activation |
JASPAR motifs
| Motif | Name | Family |
|---|---|---|
| MA0887.1 | EVX1 | HOX |
| MA0887.2 | EVX1 | HOX |
| MA1960.1 | MGA::EVX1 | TBX6-related factors::HOX |
| MA1960.2 | MGA::EVX1 | TBX6-related factors::HOX |
JASPAR matrix evidence (PMIDs): PMID:18585359, PMID:24218641
Upstream regulators (CollecTRI, top): GSC
miRNA regulators (miRDB)
62 targeting EVX1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-574-5P | 100.00 | 66.01 | 989 |
| HSA-MIR-4262 | 100.00 | 73.26 | 3931 |
| HSA-MIR-9-5P | 100.00 | 72.28 | 2361 |
| HSA-MIR-181A-5P | 99.99 | 72.96 | 2995 |
| HSA-MIR-181B-5P | 99.99 | 72.97 | 2996 |
| HSA-MIR-181C-5P | 99.99 | 72.95 | 2996 |
| HSA-MIR-181D-5P | 99.99 | 73.04 | 2997 |
| HSA-MIR-4267 | 99.96 | 66.53 | 2368 |
| HSA-MIR-6783-3P | 99.89 | 67.92 | 2059 |
| HSA-MIR-1343-3P | 99.89 | 66.78 | 1815 |
| HSA-MIR-137-3P | 99.87 | 74.74 | 2401 |
| HSA-MIR-4447 | 99.85 | 67.81 | 2900 |
| HSA-MIR-204-5P | 99.79 | 71.62 | 2439 |
| HSA-MIR-211-5P | 99.79 | 71.65 | 2440 |
| HSA-MIR-4766-5P | 99.75 | 69.23 | 2662 |
| HSA-MIR-1825 | 99.72 | 68.11 | 1089 |
| HSA-MIR-4755-5P | 99.71 | 70.34 | 2716 |
| HSA-MIR-5006-3P | 99.71 | 70.26 | 2728 |
| HSA-MIR-6892-3P | 99.68 | 66.40 | 1178 |
| HSA-MIR-466 | 99.67 | 70.85 | 2863 |
| HSA-MIR-4310 | 99.59 | 68.84 | 2527 |
| HSA-MIR-6716-5P | 99.56 | 68.62 | 1244 |
| HSA-MIR-4672 | 99.50 | 71.58 | 2893 |
| HSA-MIR-4441 | 99.49 | 66.56 | 3216 |
| HSA-MIR-3915 | 99.45 | 68.49 | 1905 |
| HSA-MIR-4735-5P | 99.43 | 68.49 | 1780 |
| HSA-MIR-208A-5P | 99.42 | 70.83 | 1913 |
| HSA-MIR-208B-5P | 99.42 | 70.83 | 1952 |
| HSA-MIR-4312 | 99.34 | 67.30 | 511 |
| HSA-MIR-3064-5P | 99.26 | 66.13 | 1497 |
Literature-anchored findings (GeneRIF, showing 2)
- Even-skipped homeobox 1 controls human embryonic stem cell differentiation by directly repressing Goosecoid expression. (PMID:22178155)
- Low EVX1 expression is Correlated with Aggressiveness of Esophageal Squamous Cell Carcinoma. (PMID:26552663)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | EVX1 | ENSDARG00000100087 |
| mus_musculus | Evx1 | ENSMUSG00000005503 |
| rattus_norvegicus | Evx1 | ENSRNOG00000046734 |
Paralogs (50): ARX (ENSG00000004848), PAX6 (ENSG00000007372), PAX7 (ENSG00000009709), ALX4 (ENSG00000052850), GSC2 (ENSG00000063515), PITX1 (ENSG00000069011), PAX2 (ENSG00000075891), RHOXF1 (ENSG00000101883), CRX (ENSG00000105392), PAX4 (ENSG00000106331), NOBOX (ENSG00000106410), PITX3 (ENSG00000107859), PHOX2B (ENSG00000109132), OTX1 (ENSG00000115507), PRRX1 (ENSG00000116132), VSX2 (ENSG00000119614), ESX1 (ENSG00000123576), PAX8 (ENSG00000125618), PAX1 (ENSG00000125813), RHOXF2 (ENSG00000131721), GSC (ENSG00000133937), RAX (ENSG00000134438), PAX3 (ENSG00000135903), ALX3 (ENSG00000156150), HESX1 (ENSG00000163666), PITX2 (ENSG00000164093), UNCX (ENSG00000164853), PHOX2A (ENSG00000165462), OTX2 (ENSG00000165588), DRGX (ENSG00000165606), PRRX2 (ENSG00000167157), SHOX2 (ENSG00000168779), OTP (ENSG00000171540), RAX2 (ENSG00000173976), EVX2 (ENSG00000174279), PROP1 (ENSG00000175325), ISX (ENSG00000175329), ALX1 (ENSG00000180318), MIXL1 (ENSG00000185155), SHOX (ENSG00000185960)
Protein
Protein identifiers
Homeobox even-skipped homolog protein 1 — P49640 (reviewed: P49640)
Alternative names: EVX-1
All UniProt accessions (3): P49640, F8W9J5, J3QQJ1
UniProt curated annotations — full annotation on UniProt →
Function. May play a role in the specification of neuronal cell types.
Subcellular location. Nucleus.
Similarity. Belongs to the even-skipped homeobox family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| P49640-1 | 1 | yes |
| P49640-2 | 2 |
RefSeq proteins (3): NP_001291448, NP_001291449, NP_001980* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001356 | HD | Domain |
| IPR009057 | Homeodomain-like_sf | Homologous_superfamily |
| IPR017970 | Homeobox_CS | Conserved_site |
| IPR020479 | HD_metazoa | Domain |
| IPR052002 | Even-skipped_HD | Family |
Pfam: PF00046
UniProt features (6 total): region of interest 2, chain 1, DNA-binding region 1, compositionally biased region 1, splice variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P49640-F1 | 57.95 | 0.16 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 115 (showing top):
GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, RNGTGGGC_UNKNOWN, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, BENPORATH_ES_WITH_H3K27ME3, GRUETZMANN_PANCREATIC_CANCER_DN, PAX4_01, ENK_UV_RESPONSE_KERATINOCYTE_UP, GOBP_NEUROGENESIS, RIZKI_TUMOR_INVASIVENESS_3D_DN, GGGTGGRR_PAX4_03, FOXD3_01, CREB_Q4, GOBP_NEURON_MIGRATION, CREB_Q2_01, LYF1_01
GO Biological Process (7): regulation of transcription by RNA polymerase II (GO:0006357), embryo development ending in birth or egg hatching (GO:0009792), ventral spinal cord interneuron specification (GO:0021521), positive regulation of transcription by RNA polymerase II (GO:0045944), spinal cord interneuron axon guidance (GO:0097377), interneuron migration (GO:1904936), regulation of DNA-templated transcription (GO:0006355)
GO Molecular Function (5): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription factor activity (GO:0003700), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677)
GO Cellular Component (5): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), axon (GO:0030424), neuronal cell body (GO:0043025)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| regulation of DNA-templated transcription | 2 |
| transcription by RNA polymerase II | 2 |
| regulation of transcription by RNA polymerase II | 2 |
| RNA polymerase II transcription regulatory region sequence-specific DNA binding | 2 |
| cellular anatomical structure | 2 |
| embryo development | 1 |
| neuron fate specification | 1 |
| cell fate specification involved in pattern specification | 1 |
| ventral spinal cord interneuron fate commitment | 1 |
| positive regulation of DNA-templated transcription | 1 |
| interneuron axon guidance | 1 |
| neuron migration | 1 |
| DNA-templated transcription | 1 |
| regulation of gene expression | 1 |
| regulation of RNA biosynthetic process | 1 |
| cis-regulatory region sequence-specific DNA binding | 1 |
| chromatin | 1 |
| DNA-binding transcription factor activity | 1 |
| transcription cis-regulatory region binding | 1 |
| transcription regulator activity | 1 |
| double-stranded DNA binding | 1 |
| sequence-specific DNA binding | 1 |
| nucleic acid binding | 1 |
| chromosome | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| neuron projection | 1 |
| somatodendritic compartment | 1 |
| cell body | 1 |
Protein interactions and networks
STRING
944 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| EVX1 | ISL1 | P20663 | 747 |
| EVX1 | LHX1 | P48742 | 746 |
| EVX1 | SPOP | O43791 | 685 |
| EVX1 | ISL2 | Q96A47 | 626 |
| EVX1 | RAB2A | P08886 | 564 |
| EVX1 | ZNF180 | Q9UJW8 | 533 |
| EVX1 | LHX3 | Q9UBR4 | 509 |
| EVX1 | GRIN1 | P35437 | 497 |
| EVX1 | PAX2 | Q02962 | 491 |
| EVX1 | FOXA2 | Q9Y261 | 475 |
| EVX1 | OLIG2 | Q13516 | 433 |
| EVX1 | GRIN3A | Q8TCU5 | 423 |
| EVX1 | HIBADH | P31937 | 416 |
| EVX1 | CHRD | Q9H2X0 | 414 |
| EVX1 | GRIN3B | O60391 | 413 |
| EVX1 | TBX6 | O95947 | 413 |
IntAct
0 interactions, top by confidence:
BioGRID (1): EVX1 (Affinity Capture-MS)
ESM2 similar proteins: A0A1W2PQ73, A1YF16, A1YG93, A2RU54, A5PKG8, O02786, O14813, O15353, O35602, O43638, O57601, P13297, P19419, P28360, P35548, P41969, P42580, P43687, P49640, P50223, P50548, P52946, P52950, P63156, P63157, P70459, P78413, Q03358, Q14549, Q2VL78, Q2VL79, Q2VL82, Q2VL83, Q2VL84, Q2VL85, Q2VL86, Q2VL87, Q2VL88, Q5NSW5, Q61575
Diamond homologs: A1YGA4, A2RU54, A2T7T2, A6NCS4, A6NHT5, A8XJD0, G5EE18, M0R6D8, O08686, O35767, O42173, O42230, O43711, O43763, O55144, O57601, O88181, O93366, O93367, O93590, O95231, P15142, P18488, P20269, P22544, P22807, P22809, P23683, P31264, P31314, P42581, P42582, P42583, P43345, P43687, P43688, P48031, P49640, P50219, P50221
SIGNOR signaling
2 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| EVX1 | “down-regulates quantity by repression” | GSC | “transcriptional regulation” |
| GSC | “down-regulates quantity by repression” | EVX1 | “transcriptional regulation” |
Disease & clinical
Clinical variants and AI predictions
ClinVar
76 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 1 |
| Likely pathogenic | 0 |
| Uncertain significance | 73 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 58544 | GRCh38/hg38 7p15.2(chr7:27154807-27422335)x1 | Pathogenic |
SpliceAI
452 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 7:27245301:CAAG:C | donor_loss | 1.0000 |
| 7:27245303:AGG:A | donor_loss | 1.0000 |
| 7:27245306:T:A | donor_loss | 1.0000 |
| 7:27245881:CCCA:C | acceptor_loss | 1.0000 |
| 7:27245884:A:AG | acceptor_gain | 1.0000 |
| 7:27245884:AG:A | acceptor_gain | 1.0000 |
| 7:27245884:AGGT:A | acceptor_gain | 1.0000 |
| 7:27245885:G:GA | acceptor_gain | 1.0000 |
| 7:27245885:GG:G | acceptor_gain | 1.0000 |
| 7:27245885:GGT:G | acceptor_gain | 1.0000 |
| 7:27245885:GGTG:G | acceptor_gain | 1.0000 |
| 7:27245885:GGTGT:G | acceptor_gain | 1.0000 |
| 7:27245019:C:G | acceptor_gain | 0.9900 |
| 7:27245020:A:AG | acceptor_gain | 0.9900 |
| 7:27245021:C:G | acceptor_gain | 0.9900 |
| 7:27245303:AG:A | donor_gain | 0.9900 |
| 7:27245304:GG:G | donor_gain | 0.9900 |
| 7:27245305:G:GG | donor_gain | 0.9900 |
| 7:27245020:AC:A | acceptor_gain | 0.9800 |
| 7:27245300:TCAAG:T | donor_gain | 0.9800 |
| 7:27245018:A:AG | acceptor_gain | 0.9700 |
| 7:27245018:ACAC:A | acceptor_gain | 0.9700 |
| 7:27245021:C:CA | acceptor_gain | 0.9700 |
| 7:27245046:AG:A | acceptor_gain | 0.9700 |
| 7:27245047:GG:G | acceptor_gain | 0.9700 |
| 7:27245305:GTAT:G | donor_gain | 0.9700 |
| 7:27243529:G:GT | donor_gain | 0.9600 |
| 7:27245301:CAAGG:C | donor_gain | 0.9600 |
| 7:27245302:AAG:A | donor_gain | 0.9600 |
| 7:27245302:AAGG:A | donor_gain | 0.9600 |
AlphaMissense
2590 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 7:27245179:C:A | R187S | 1.000 |
| 7:27245179:C:G | R187G | 1.000 |
| 7:27245179:C:T | R187C | 1.000 |
| 7:27245183:C:T | T188I | 1.000 |
| 7:27245186:C:A | A189D | 1.000 |
| 7:27245188:T:A | F190I | 1.000 |
| 7:27245188:T:C | F190L | 1.000 |
| 7:27245188:T:G | F190V | 1.000 |
| 7:27245189:T:C | F190S | 1.000 |
| 7:27245189:T:G | F190C | 1.000 |
| 7:27245190:C:A | F190L | 1.000 |
| 7:27245190:C:G | F190L | 1.000 |
| 7:27245192:C:T | T191I | 1.000 |
| 7:27245201:A:C | Q194P | 1.000 |
| 7:27245201:A:G | Q194R | 1.000 |
| 7:27245202:G:C | Q194H | 1.000 |
| 7:27245202:G:T | Q194H | 1.000 |
| 7:27245204:T:G | I195S | 1.000 |
| 7:27245213:T:A | L198Q | 1.000 |
| 7:27245213:T:C | L198P | 1.000 |
| 7:27245213:T:G | L198R | 1.000 |
| 7:27245215:G:A | E199K | 1.000 |
| 7:27245216:A:C | E199A | 1.000 |
| 7:27245216:A:T | E199V | 1.000 |
| 7:27245217:G:C | E199D | 1.000 |
| 7:27245217:G:T | E199D | 1.000 |
| 7:27245221:G:A | E201K | 1.000 |
| 7:27245224:T:A | F202I | 1.000 |
| 7:27245224:T:C | F202L | 1.000 |
| 7:27245224:T:G | F202V | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1000968982 (7:27243853 G>A), RS1000998666 (7:27243567 G>A,C), RS1001682756 (7:27247092 C>G,T), RS1001962185 (7:27242565 C>T), RS1002920580 (7:27246580 A>C,G), RS1002972974 (7:27241496 A>C), RS1003004198 (7:27241191 G>A,C), RS1003235518 (7:27243783 C>A), RS1003299923 (7:27246342 T>C), RS1003667529 (7:27245664 C>A,T), RS1003718445 (7:27243426 C>A), RS1004663944 (7:27240840 C>T), RS1004982588 (7:27244676 A>G), RS1005064453 (7:27245808 C>G,T), RS1005320398 (7:27244826 A>C)
Disease associations
OMIM: gene MIM:142996 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
31 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000675_7 | Heart failure | 7.000000e-06 |
| GCST002143_1 | Blood pressure | 2.000000e-09 |
| GCST002143_5 | Blood pressure | 2.000000e-12 |
| GCST002831_8 | Lead levels in blood | 4.000000e-06 |
| GCST004384_5 | Hypertension | 9.000000e-09 |
| GCST004385_8 | Systolic blood pressure | 5.000000e-10 |
| GCST004386_13 | Diastolic blood pressure | 2.000000e-11 |
| GCST004386_7 | Diastolic blood pressure | 2.000000e-06 |
| GCST004388_29 | Blood pressure traits (multi-trait analysis) | 7.000000e-07 |
| GCST004388_30 | Blood pressure traits (multi-trait analysis) | 1.000000e-06 |
| GCST004388_4 | Blood pressure traits (multi-trait analysis) | 2.000000e-11 |
| GCST004388_5 | Blood pressure traits (multi-trait analysis) | 2.000000e-09 |
| GCST006166_4 | Diastolic blood pressure x alcohol consumption interaction (2df test) | 4.000000e-19 |
| GCST006166_61 | Diastolic blood pressure x alcohol consumption interaction (2df test) | 5.000000e-11 |
| GCST006167_21 | Mean arterial pressure x alcohol consumption interaction (2df test) | 2.000000e-08 |
| GCST006167_5 | Mean arterial pressure x alcohol consumption interaction (2df test) | 4.000000e-17 |
| GCST006167_78 | Mean arterial pressure x alcohol consumption interaction (2df test) | 1.000000e-09 |
| GCST006169_17 | Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test) | 4.000000e-11 |
| GCST006169_36 | Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test) | 4.000000e-08 |
| GCST006170_2 | Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test) | 3.000000e-09 |
| GCST006170_38 | Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test) | 8.000000e-13 |
| GCST006172_1 | Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test) | 1.000000e-13 |
| GCST006172_22 | Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test) | 2.000000e-09 |
| GCST006364_3 | Hepatitis B surface antigen seroclearance in chronic hepatitis B infection | 3.000000e-06 |
| GCST006434_8 | Systolic blood pressure x alcohol consumption interaction (2df test) | 9.000000e-23 |
| GCST006979_338 | Heel bone mineral density | 5.000000e-18 |
| GCST007094_63 | Diastolic blood pressure | 5.000000e-09 |
| GCST007096_76 | Pulse pressure | 3.000000e-06 |
| GCST007098_83 | Diastolic blood pressure | 3.000000e-06 |
| GCST007098_84 | Diastolic blood pressure | 9.000000e-06 |
EFO canonical traits (7, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0006336 | diastolic blood pressure |
| EFO:0006335 | systolic blood pressure |
| EFO:0005763 | pulse pressure measurement |
| EFO:0004329 | alcohol drinking |
| EFO:0006340 | mean arterial pressure |
| EFO:0009345 | Hepatitis B virus surface antigen seropositivity |
| EFO:0009270 | heel bone mineral density |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
16 total (human), top 16 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| tamibarotene | decreases expression | 1 |
| abrine | increases expression | 1 |
| bisphenol S | decreases methylation | 1 |
| Resveratrol | affects cotreatment, decreases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Arsenic | affects methylation | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Folic Acid | decreases expression | 1 |
| Gold | increases expression | 1 |
| Plant Extracts | affects cotreatment, decreases expression | 1 |
| Tretinoin | decreases expression | 1 |
| Aflatoxin B1 | decreases methylation | 1 |
| Asbestos, Crocidolite | decreases methylation | 1 |
| Asbestos, Amosite | decreases methylation | 1 |
| Antirheumatic Agents | decreases expression | 1 |
| Particulate Matter | increases abundance, increases expression | 1 |
Cellosaurus cell lines
3 cell lines: 3 embryonic stem cell
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_A1P6 | SEES3-1V human EVX1, clone1 | Embryonic stem cell | Male |
| CVCL_A1P7 | SEES3-1V human EVX1, clone2 | Embryonic stem cell | Male |
| CVCL_A1P8 | SEES3-1V human EVX1, clone3 | Embryonic stem cell | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): heart failure